PMID- 34893949
OWN - NLM
STAT- MEDLINE
DCOM- 20220107
LR  - 20220107
IS  - 2095-0225 (Electronic)
IS  - 2095-0217 (Linking)
VI  - 15
IP  - 6
DP  - 2021 Dec
TI  - Status of hyperhomocysteinemia in China: results from the China Stroke High-risk 
      Population Screening Program, 2018.
PG  - 903-912
LID - 10.1007/s11684-021-0871-4 [doi]
AB  - A nationwide survey was conducted from October 2018 to September 2019 to assess 
      the prevalence of hyperhomocysteinemia (Hhcy) and its influencing factors in 
      China. A standardized questionnaire was used to collect information. Hhcy was 
      defined as the level of serum homocysteine (HCY) ⩾ 15.0micromol/L. The H-type 
      hypertension (HHYP) was defined as hypertension with an elevated serum HCY 
      15.0micromol/L). Finally, 110 551 residents ⩾ 40 years of age from 31 provinces in 
      the mainland of China were included. Overall, the median serum HCY level was 
      10.9micromol/L (interquartile range 7.9-15.1). A total of 28 633 participants (25.9%) 
      were defined as Hhcy. The Hhcy prevalence ranged from 7.9% in Shanghai to 56.8% 
      in Tianjin. The data showed that serum HCY levels were associated with age, male 
      gender, cigarette smoking, hypertension, diabetes, ethnicity, endurance in 
      exercise (inverse), and fruit and vegetable intake (inverse). In addition, 15 486 
      participants were defined as HHYP, and the rate was 14.0%. HHYP was an 
      independent predictor of stroke with an adjusted odds ratio of 1.752 (95% CI 
      1.338-2.105). The geographical distribution pattern of the Hhcy epidemic reflects 
      dynamic differences, and national strategies should be carried out to further 
      improve the care of patients with Hhcy across China.
CI  - (c) 2021. Higher Education Press.
FAU - Tu, Wenjun
AU  - Tu W
AD  - Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Tianjin, 300192, China.
AD  - The General Office of Stroke Prevention Project Committee, National Health 
      Commission of the People's Republic of China, Beijing, 100053, China.
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, 100070, China.
FAU - Yan, Feng
AU  - Yan F
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, 
      100053, China.
FAU - Chao, Baohua
AU  - Chao B
AD  - The General Office of Stroke Prevention Project Committee, National Health 
      Commission of the People's Republic of China, Beijing, 100053, China.
FAU - Ji, Xunming
AU  - Ji X
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, 
      100053, China. jixm@ccmu.edu.cn.
FAU - Wang, Longde
AU  - Wang L
AD  - The General Office of Stroke Prevention Project Committee, National Health 
      Commission of the People's Republic of China, Beijing, 100053, China. 
      wangld_csppc@126.com.
LA  - eng
PT  - Journal Article
DEP - 20211210
PL  - China
TA  - Front Med
JT  - Frontiers of medicine
JID - 101549428
SB  - IM
MH  - China/epidemiology
MH  - Humans
MH  - *Hyperhomocysteinemia/diagnosis/epidemiology
MH  - *Hypertension/epidemiology
MH  - Male
MH  - Prevalence
MH  - Risk Factors
MH  - *Stroke/epidemiology
OTO - NOTNLM
OT  - Chinese
OT  - H-type hypertension
OT  - homocysteine
OT  - hyperhomocysteinemia
EDAT- 2021/12/12 06:00
MHDA- 2022/01/08 06:00
CRDT- 2021/12/11 06:16
PHST- 2020/11/20 00:00 [received]
PHST- 2021/05/29 00:00 [accepted]
PHST- 2021/12/12 06:00 [pubmed]
PHST- 2022/01/08 06:00 [medline]
PHST- 2021/12/11 06:16 [entrez]
AID - 10.1007/s11684-021-0871-4 [pii]
AID - 10.1007/s11684-021-0871-4 [doi]
PST - ppublish
SO  - Front Med. 2021 Dec;15(6):903-912. doi: 10.1007/s11684-021-0871-4. Epub 2021 Dec 
      10.